Figure 1.

KRAS mutations are shared neoantigens. A. Summary of the peptides used to assess KRAS Radium TCRs specificities. These peptides represent various KRAS mutations found in the population. Mutation frequencies are based on.³³

B. T cell clones 27, 48, 57 and 61 from pancreatic cancer patient 705 were tested against autologous EBV-LCLs loaded with several KRAS mutant peptides contained in the vaccine and KRAS WT peptide. Peptide-specific T cell proliferation was measured in ³H-thymidine incorporation assays and displayed as stimulation index (SI). An SI ≥2 was considered a positive response. C. The HLA restriction of the T-cell clones was identified by blocking the T-cell proliferation with anti-HLA-DR, -DQ, and -DP antibodies. Examples for each clone are shown (yellow, red, blue). For clone 57 (green), the corresponding Radium-12 TCR transduced T cells were used due to insufficient material for testing.